Themis Medicare Limited shareholders approved the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, during the company's 56th Annual General Meeting held on September 30, 2026.

The meeting, conducted at the registered office in Vapi, Gujarat, also saw the re-appointment of Mr. Rajneesh Anand as a director retiring by rotation. The board recommended a dividend on equity shares for FY26, which was duly approved by the members present and voting via electronic means.

Meeting proceedings and key approvals

The annual general meeting commenced at 11:00 am and concluded by 11:35 am. Dr. Dinesh S. Patel, Chairman of the company, presided over the session. Mr. Sundarrajan, partner of M/s. Krishnaan & Co., the statutory auditors, attended the meeting to address queries related to the audit report.

Shareholders voted on several ordinary and special business items. Remote e-voting was open from September 27 to September 29, 2026, while physical ballot papers were available for attendees who had not cast votes electronically. Mr. Ketan R. Shirwadkar of M/s. KRS AND CO. served as the scrutinizer for the voting process.

Resolutions passed

The following resolutions were put to vote and approved by the shareholders:

The Managing Director and CEO provided an update on the company's business activities during the session. Members raised queries regarding the financial statements, which were satisfactorily addressed by the management before the voting process began.

The results of the e-voting and ballot paper voting are scheduled to be disseminated to stock exchanges and uploaded on the company's website within two working days of the meeting's conclusion.

Themis Medicare Limited has withdrawn its proposed preferential issue of 45,95,795 convertible equity warrants. The company cited that its working capital requirements, which were the primary objective of the issue, have been met through alternative means.

The withdrawal decision was taken on September 24, 2026. The proposal originally involved issuing warrants to a promoter group entity at a price of ₹102.87 per warrant. This action follows earlier intimations dated February 25, 2026, and March 10, 2026, regarding the Board's approval of the same.

Reasons for withdrawal

The company stated that the decision allows it to consider fresh issues in the future with objects as may be necessary or to meet requirements as and when they arise. The original objective of strengthening the working capital position has been achieved without this specific equity-linked instrument.

Themis Medicare had applied for in-principal approval from both BSE Limited and National Stock Exchange of India Limited for the proposed issue. The company confirmed it will withdraw these applications and that all prior disclosures and submissions related to the preferential issue are treated as withdrawn.

Impact on operations

Management clarified that the withdrawal of the proposed issue will not have any adverse impact on the financial position or operations of the company. The move signifies a shift in capital structure strategy rather than a change in operational outlook.

What the numbers show

The withdrawal highlights a divergence between planned external fundraising and actual liquidity management. While the initial plan sought to raise approximately ₹47.28 crore (calculated from 45,95,795 warrants × ₹102.87) via promoter infusion to bolster working capital, the company now indicates these needs are satisfied internally or through other channels. This suggests improved cash flow generation or alternative debt arrangements have rendered the dilutive equity warrant issuance unnecessary.